The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted priority review for US-based biopharmaceutical company AbbVie’s glecaprevir / pibrentasvir (G / P) cure to treat all major genotypes (GT1-6) of the chronic hepatitis C virus (HCV).

G / P is an investigational, pan-genotypic, ribavirin-free treatment that can be administered once daily to a patient affected with chronic HCV.

AbbVie executive vice-president, research and development and chief scientific officer Dr Michael Severino said: “We will work closely with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) as part of our commitment to provide a potential cure for as many people living with HCV as possible.

"We will work closely with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) as part of our commitment to provide a potential cure for as many people living with HCV as possible."

“We are pleased that G/P has now been recognised as a potential important therapy for people living with HCV through the receipt of priority review designations by regulatory authorities in Japan, the European Union (EU) and the US.”

AbbVie’s G/P, if approved, is expected to offer a shorter treatment with duration of eight weeks for patients affected with GT1 and GT2 HCV without cirrhosis, and an additional treatment option for patients with GT3 to GT6.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The cure can also be used to meet the requirements of patients with specific treatment challenges, such as the ones with severe chronic kidney disease (CKD) and those who are not cured with a previous direct-acting anti-viral (DAA).

AbbVie was granted the European Medicines Agency (EMA) accelerated assessment in December last year, and the US Food and Drug Administration (FDA) priority review designations in January this year.


Image: Electron micrographs of hepatitis C virus purified from cell culture. Photo: courtesy of the Center for the Study of Hepatitis C, The Rockefeller University / Charles Rice.